Pfizer Inc. (NYSE:PFE) Position Increased by WCM Investment Management LLC

WCM Investment Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 337.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 50,675 shares of the biopharmaceutical company’s stock after acquiring an additional 39,085 shares during the period. WCM Investment Management LLC’s holdings in Pfizer were worth $1,474,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth about $29,000. Quarry LP purchased a new stake in Pfizer during the second quarter valued at about $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer during the second quarter valued at about $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer in the first quarter worth about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 0.2 %

PFE stock opened at $26.18 on Wednesday. The firm has a market cap of $148.36 billion, a PE ratio of 35.38, a PEG ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a fifty day simple moving average of $28.84 and a 200 day simple moving average of $28.67. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company posted ($0.17) EPS. The firm’s revenue was up 31.2% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.42%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.